Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Formularies as Topic”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,081 records · Page 60Linked to original sources
PubMed2003

Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.

BACKGROUND: To have a drug listed in a province's formulary, manufacturers must submit an application providing data required by the provincial rules and guidelines. The procedures for the scientific evaluation of drugs considered for listing for reimbursement in five provinces have been examined previously. OBJECTIVE: The present study investigates the clarity of the same five provinces' rules and guidelines about effectiveness and cost data that should be included in listing submissions from the perspective of the pharmaceutical company. METHODS: The manufacturers of five recently introduced drugs selected by the investigators received questionnaires asking about the departments within their companies that are responsible for the submission, the data required by each of the five provinces and the clarity of each province's requirements for submission. Each company was also asked similar questions about its own submission experience with its drug. Investigators visited each manufacturer to review the questionnaires and answer questions. RESULTS: The manufacturers perceived the rules and guidelines on effectiveness and economic data of several provinces as being neither clear nor consistent. Consequently, information that companies submit in their attempts at compliance with the rules and guidelines varies substantially. CONCLUSIONS: The manufacturers' perceptions of the information required by the provinces on effectiveness and cost information were inconsistent. Previous work indicated that the provinces make significant decisions about listings based on inadequate information resulting in a scientifically flawed system that contributes to considerable inequality in access to new drugs between provinces. The findings of the present work reinforce this conclusion.

Canada↗
PubMed2003

Dry eye moves beyond palliative therapy.

Keratoconjunctivitis sicca, or dry eye syndrome, is a complex condition characterized by inflammation of the ocular surface and tear-producing glands. Emerging awareness of the etiology of dry eye has led to the development of highly effective therapy. When dry eye is controlled, there is significant potential for cost savings.

Age Factors↗
PubMed2002

British Columbia poised to reduce drug coverage.

The government of British Columbia is reviewing its Pharmacare program and plans to de-list drugs currently covered. The British Columbia Persons with AIDS Society has objected to the plan and has called on the government to consider other ways of addressing the rising costs of prescription drugs.

Anti-HIV Agents↗
PubMed2004

Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.

OBJECTIVES: To examine patient attitudes related to formulary medications and medication-related decision making in multitier copayment prescription drug plans. STUDY DESIGN: A cross-sectional retrospective analysis. METHODS: Data were collected via mail survey from a random sample of 25,008 members of a managed care organization. The selected members were enrolled in a variety of 2- and 3-tier copayment plans and were taking prescription medication to treat 1 or more of 5 chronic disease states. RESULTS: Most respondents did not believe that formulary drugs were safer or more effective than nonformulary drugs, but 39.7% thought that formulary drugs were relatively less expensive. Most respondents appeared willing to consider switching from a nonformulary drug to a formulary drug with a lower copayment. The percent of respondents who reported they would be very unlikely or unlikely to switch was only 15.3% for a new prescription and 24.2% for a refill prescription. Medication efficacy and physician opinion were important factors in plan members' switching decisions. Cost was an important factor for some members, but older plan members were less likely to report that cost was important. CONCLUSIONS: Multitier plan members generally believed that drugs are placed on the formulary for reasons of cost rather than safety or efficacy. Most plan members were receptive to switching from a nonformulary to a formulary medication, but financial incentives alone may not convince some plan members to make the switch.

Adult↗
PubMed2004

Physician satisfaction with formulary policies: is it access to formulary or nonformulary drugs that matters most?

OBJECTIVE: To assess physician satisfaction with Department of Veterans Affairs (VA) formulary policies and to examine the correlation between physician satisfaction and perceived access to formulary and nonformulary medications. STUDY DESIGN: Cross-sectional survey with specific questions on access to formulary and nonformulary medications. Statistical analyses included assessment of associations between physician satisfaction and various measures of access. PARTICIPANTS AND METHODS: Initial sample of 4015 staff physicians working in VA healthcare facilities. Responses were received from 1812 (49%) of the 3682 physicians in the final eligible sample population. RESULTS: Most clinicians (72%) reported that their local formulary covered more than 90% of the medications they wanted to prescribe. Most (73%) agreed that drug restrictions were important to contain costs, and 86% agreed that it was important for VA to choose "best-value" drugs. Respondents reported an 89% approval rate for nonformulary drugs, though 31% indicated that approvals routinely took 3 or more days. We found strong associations between physician satisfaction and self-reported approval rates for nonformulary drugs (P = .001), timely approval of nonformulary requests (P < .001), and percentage of nonformulary prescriptions as a proportion of overall prescriptions at a regional level (P< .01). There was no significant correlation between physician satisfaction and number of medications added to regional formularies or with drug costs per unique patient. CONCLUSIONS: VA physicians were generally supportive of VA formulary policies including choosing best-value drugs to control pharmaceutical expenditures. Nevertheless, access to nonformulary drugs and timely approval of requests for nonformulary medications were strong predictors of clinician satisfaction and support for cost-containment measures.

Attitude of Health Personnel↗
PubMed2004

Consumer knowledge and perceptions of formularies.

A study was undertaken to determine consumer knowledge and perceptions of formularies. A prevalidated survey containing 11 scored items was administered to 714 consumers waiting to receive prescription medications at 72 community pharmacies in Houston. Overall, these consumers were satisfied with their prescription insurance plans, but their attitudes toward formularies were negative, and the negative perceptions were significantly correlated with satisfaction scores. However, only 25% of the surveyed population had a copy of the formulary, so that a large majority had no knowledge of their formulary or the types of drugs it covered. Efforts to educate patients may reduce the difficulty faced by pharmacists in explaining formulary issues to consumers.

Adolescent↗
PubMed2004

Clinical management. The late show.

The new GP contract will be a catalyst for nurse prescribing. With most GPs choosing to exercise their right to opt out of out-of-hours care, nurse prescribing will be a key part of establishing new multidisciplinary teams. Factors hindering progress may include nursing shortages and limitations of the independent nurse formulary.

After-Hours Care↗
PubMed2003

[A study on formulas of Ettyu-Hangontan during the Edo period].

Since 1640, Borneol was brought to Nagasaki from South-East Asia by the Dutch ships. As a result, it was introduced as a component unique to "Hangontan" which was distributed by the pill-peddler of Toyama during the Edo period. We intend to discuss how to bring about such a formula for the "Hangontan" of Toyama.

Asia, Southeastern↗